TrialCancer medicine2023

Pembrolizumab plus chemotherapy in Japanese patients with triple-negative breast cancer: Results from KEYNOTE-355.

Masaya Hattori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.